Amyloidosis: Up-to-date

Amyloidosis is mainly a systemic disease belonging to protein-folding diseases. The past 10 years have shown significant progress in typing and the clinical management of amyloidosis, in the identification of novel prognostic markers for risk-stratification, and also in the development of new therap...

Full description

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2016-08, Vol.37 (8), p.529-535
Main Author: Magy-Bertrand, N
Format: Article
Language:fre
Subjects:
Amyloidosis - diagnosis
Amyloidosis - therapy
Biomarkers - analysis
Disease Management
Humans
Prognosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amyloidosis is mainly a systemic disease belonging to protein-folding diseases. The past 10 years have shown significant progress in typing and the clinical management of amyloidosis, in the identification of novel prognostic markers for risk-stratification, and also in the development of new therapeutic agents. Biological molecular techniques are now able to type amyloidosis which were unidentified. Cardiac MRI and biomarkers allow a precise risk-stratification, especially in AL amyloidosis. If necessary, this prognostic evaluation may lead to rapid changes in the chemotherapy treatment. Emerging treatments rely on biotherapies, gene therapy, immunotherapy and blocking analogous agents. They give hope about an increase of survival of patients with systemic amyloidosis.
ISSN:1768-3122
DOI:10.1016/j.revmed.2015.12.029